PINK
Simplify Health Care ETF
PINK is an actively managed fund of US healthcare stocks and/or ETFs. The fund seeks long-term capital growth and commits to donate its net profit, in the form of its annual management fee to the Susan G. Komen Breast Cancer Foundation.
US
EQUITY
Active
MANAGEMENT STYLE
$ 342.9 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Oct 07, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ELI LILLY & CO | 10.2 % |
| HUMANA INC | 7.2 % |
| ARCUTIS BIOTHERAPEUTICS INC | 6.6 % |
| WARBY PARKER, INC. CLASS A | 5.1 % |
| ABBVIE INC | 4.8 % |
| THERMO FISHER SCIENTIFIC INC | 4.7 % |
| JOHNSON & JOHNSON | 4.6 % |
| UNITEDHEALTH GROUP INC | 4.4 % |
| PURECYCLE TECHNOLOGIES INC | 4.2 % |
| AVANTOR, INC. | 4.2 % |
Constituent Breakdown
| Number of holdings | 53 |
| Herfindahl-Hirschman Index | 430 |
| Wgt avg mkt cap (mns) | $213,546 |
| Large cap (>$10bn) | 71.3% |
| Mid cap ($2-10bn) | 17.8% |
| Small cap (<$2bn) | 5.8% |
| Developed mkts. | 93.4% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 89.9 % |
 |
IRELAND | 3.6 % |
 |
COSTA RICA | 1.1 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 5.5% | 21.7% | 8.4% | 15.4% | -- | -- | -- | 9.1% |
| Dividend Yield | 0.3% | 0.7% | 0.6% | 0.6% | -- | -- | -- | 0.4% |
| Total Returns | 5.8% | 22.4% | 9.0% | 16.0% | -- | -- | -- | 9.5% | Ann. Volatility | 18.6% | 18.3% | 18.7% | 17.3% | -- | -- | -- | 17.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.75 | 28% |
| MSCI EAFE | 0.62 | 28% |
| MSCI Emg Mkts | 0.26 | 13% |
Liquidity Measures
| Avg. volume (000) | 91 |
| ADV traded (mns) | $3 |
| Turnover | 1.0% |
| Avg. Bid/Ask (% of price) | 0.21% |
Technical Indicators
| 30d moving avg. (EMA) | $39.27 |
| Relative strength (RSI) | 57 |
| MACD/Signal | 0.35/0.35 |
| Bollinger Bands (Upper/Lower) | $40.62/$38.10 |
| Short interest (% of AUM) | 0.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PINK |
Expenses vs. PINK |
ALTAR Score™ vs. PINK |
|---|---|---|---|---|
| VHT | Vanguard Health Care ETF | 42.2% | -41 bp | +5.1% |
| FHLC | Fidelity MSCI Health Care Index ETF | 42.2% | -42 bp | +5.3% |
| XLV | Health Care Select Sector SPDR | 42.0% | -42 bp | +6.5% |
| IYH | iShares U.S. Healthcare ETF | 40.9% | -10 bp | +5.8% |
| IXJ | iShares Global Healthcare ETF | 39.2% | -8 bp | +6.3% |
| JDOC | JPMorgan Healthcare Leaders ETF | 33.8% | +15 bp | +4.7% |
| HRTS | Tema Heart & Health ETF | 32.9% | +25 bp | +2.8% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 31.0% | +25 bp | +2.2% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 30.7% | +10 bp | +6.2% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 28.5% | -37 bp | +6.5% |
Risk and Returns: PINK vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 10/14/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,395 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.2%. PINK's ALTAR Score™ is approximately -2.5 standard
deviations above the category average. This places PINK in the 1st percentile
among funds in the category.
Sell-Side Consensus
$46.59
PRICE TARGET
+23.3%
UPSIDE